Research Area: Cell engineering & therapy
Development Stage: Prediction
Goal: Identify pre-infusion correlates to in vivo active of cell therapy and patient outcome
to follow our data >[/ce_button]
PSI of the pre-infusion CAR-T cell products showed significant correlation with the objective response of patients. The PSI, measured across a cohort of 20 patients, combined the CD4+ and CD8+ CAR-T response to CD19-K562 stimulation.
The average PSI of the responder subgroup was more than twice as high as the PSI of the non-responders, a difference that was shown to be statistically significant (p = 0.0119).1
to learn more >[/ce_button]
PSI outperformed other pre-infusion metrics, including IFN-g co-culture cytokine intensity, ratio of CD4+ to CD8+ T cells, and various T cell phenotype frequencies.
PSI was the only metric that statistically differentiated responding from non-responding patients. The correlation of PSI with clinical outcome indicates the metric’s potential as a biomarker for guiding personalized CAR-T cell treatments and predicting therapeutic efficacy.1